Skip to main
NUVL
NUVL logo

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 54%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent Inc is positioned favorably within the biopharmaceutical sector with a focus on developing targeted therapies for cancer, demonstrating a robust pipeline that includes promising candidates like NVL-520 and NVL-655 for NSCLC. The implementation of Expanded Access Programs (EAPs) indicates strong demand and a strategic approach to broaden patient access to treatments, potentially creating a wider prescriber base ahead of anticipated regulatory approvals. Furthermore, positive early clinical data, such as the 38% overall response rate (ORR) in prior TKI therapy patients for neladalkib, reflects the effectiveness of its therapies, bolstering the company's outlook as it approaches key regulatory milestones.

Bears say

Nuvalent Inc reported no revenue for the quarter, reflecting the challenges faced by clinical-stage biopharmaceutical companies that are heavily reliant on successful drug development and eventual commercialization. The company incurred a net loss of $1.05 per share, slightly better than the consensus estimate of $1.08 per share, which suggests ongoing financial strain as it continues its development phase without generating income. This absence of revenue generation, paired with substantial losses, contributes to a negative outlook on the company's financial sustainability and future growth potential.

Nuvalent (NUVL) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 54% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 13 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.